Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled$1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to$65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUS ...